Ten-Year Treatment Outcomes of Neovascular Age-Related Macular Degeneration from two regions

Macular Diseases

Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: Two-Year Results

Ophthalmology.

Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group., Writing Committee:., Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd

doi: 10.1016/j.ophtha.2020.01.029.

Macular Diseases

Association of Visit Adherence and Visual Acuity in Patients With Neovascular Age-Related Macular Degeneration: Secondary Analysis of the Comparison of Age-Related Macular Degeneration Treatment Trial

JAMA Ophthalmol.

Ramakrishnan MS, Yu Y, VanderBeek BL

doi: 10.1001/jamaophthalmol.2019.4577.

COMMENTED

Macular DiseasesRetinal Diseases

Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials (CATT)

Ophthalmology.

Jaffe GJ, Ying GS, Toth CA, Daniel E, Grunwald JE, Martin DF, Maguire MG; Comparison of Age-related Macular Degeneration Treatments Trials Research Group

doi: 10.1016/j.ophtha.

Macular Diseases

Development and testing of a patient-derived questionnaire for treatment of neovascular age-related macular degeneration: dimensions of importance in treatment of neovascular age-related macular degeneration

Acta Ophthalmol.

Jelin E, Wisløff T, Moe MC, Heiberg T

doi: 10.1111/aos.13847.

Macular Diseases

Visual Acuity Outcomes after Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report Number 19

Ophthalmol Retina.

Keenan TD, Vitale S, Agrón E, Domalpally A, Antoszyk AN, Elman MJ, Clemons TE, Chew EY, Age-Related Eye Disease Study 2 Research Group.

doi: 10.1016/j.oret.2019.06.001.

Macular Diseases

Intravitreal aflibercept for neovascular age-related macular degeneration in patients aged 90 years or older: 2-year visual acuity outcomes

Eye (Lond).

Chatziralli I, Regan SO, Mohamed R, Talks J, Sivaprasad S; UK Aflibercept Users Group.

doi: 10.1038/s41433-018-0114-3.

Macular Diseases

SMOKING STATUS AND TREATMENT OUTCOMES OF VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

Retina.

Vittorio AF, Nguyen V, Barthelmes D, Arnold JJ, Cheung CMG, Murray N, Gillies MC, Fight Retinal Blindness! Study Group.

doi: 10.1097/IAE.0000000000002679.

Macular Diseases

Association Between Cilioretinal Arteries and Advanced Age-Related Macular Degeneration: Secondary Analysis of the Comparison of Age-Related Macular Degeneration Treatment Trials (CATT)

JAMA Ophthalmol.

Bavinger JC, Ying GS, Daniel E, Grunwald JE, Maguire MG, Comparison of Age-Related Macular Degeneration Treatments Trials Research Group.

doi: 10.1001/jamaophthalmol.

Macular DiseasesRetinal Diseases

One-year outcome of intravitreal ziv-aflibercept therapy for non-responsive neovascular age-related macular degeneration

Br J Ophthalmol.

Braimah IZ, Agarwal K, Mansour A, Chhablani J; Ziv-aflibercept Study Group

doi: 10.1136/bjophthalmol-

Related content

Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: Two-Year Results

Association of Visit Adherence and Visual Acuity in Patients With Neovascular Age-Related Macular Degeneration: Secondary Analysis of the Comparison of Age-Related Macular Degeneration Treatment Trial

Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials (CATT)

Development and testing of a patient-derived questionnaire for treatment of neovascular age-related macular degeneration: dimensions of importance in treatment of neovascular age-related macular degeneration

Visual Acuity Outcomes after Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report Number 19

Intravitreal aflibercept for neovascular age-related macular degeneration in patients aged 90 years or older: 2-year visual acuity outcomes

SMOKING STATUS AND TREATMENT OUTCOMES OF VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

Association Between Cilioretinal Arteries and Advanced Age-Related Macular Degeneration: Secondary Analysis of the Comparison of Age-Related Macular Degeneration Treatment Trials (CATT)

One-year outcome of intravitreal ziv-aflibercept therapy for non-responsive neovascular age-related macular degeneration